Immune * Flashcards
(37 cards)
Prevention of infection *
Live attenuated viruses provide broader, longer lived immunity compared to inactivated types
IgG may not ensure local mucosal protection (IgA)
Three schedules for childhood vaccines- 0-6, 7-18 catch up for 4mth-18 years, one schedule for adult 19 and older
ACIP guidelines for vaccine *
Doses may be given 4 days prior/later than specified date
Give live virus vaccine at least 28 days apart
Space vaccine injections 1 inch apart no need to aspirate
Reimmunization is not harmful
Reduced doses should not be given
Recognize response to AE
Vaccine failure can occur with improper transport and storage
May have accelerated schedule for travel
Major contraindications is anaphylaxis
Any dose vaccine not given at recommended age should be given at next encounter
Combination vaccine preferred over separate injections
Dtap/Tdap*
Diphtheria and tetanus toxoid pertussis DTaP-acellular pertussis for those less than 7 years
Tdap-for those greater than 7 years
Controlling pertussis in young infants may depend on giving booster to older children/adults
Tetanus prophylaxis as part of wound care
Inactivated
4-5 doses of DTap, then Tdap at 11-12 years
Booster every 10 years or presence of wound
Tdap to be given during each pregnancy at 27-37 weeks
Polio *
Polio vaccine- only in US, concern for polio resurgence
Inactivated
Haemophilus influenza *
HI type B vaccine-pneumonia, epiglottis
Inactivated
Hepatitis *
Hepatitis A-prevent transmission to adults
Hepatitis B- given at birth/infant
HPV, complete series by 6 months, post vaccine serology 9-12 months of age or 1-2 months post last dose
Hep Bs ag and antihep Bs, may need 3 or 4 doses
Inactivated
HPV*
For females and males
Contraindicated in pregnancy
Inactivated
Influenza vaccine *
Inactivated
Formulation based on epidemiological data, annual
Meningococcal *
Inactivated
For Neisseria meningitis
Pneumococcal- PCV 13 covers 13 serotypes
PCV 23 for children greater than 2 years at high risk
Considerations for inactivated vaccine *
Fever and local reaction may occur within 24-72 hours
Anaphylaxis to prior dose, neomycin, polymyxin B or strepmycin contraindicated in IPV
Allergies to vaccine components/yeast contraindicate for HBV, IPV
Moderate to severe infection contraindicated for HPV/HIB vaccine
Considerations for live vaccine *
Consult with ID if immunocompromised
Cannot given with IGIV therapy
Bacillus calmette guerin vaccine*
Live
To prevent spread of TB not routinely used in US
MMR *
Live
Measles- more responsible for adverse reactions
Mumps
Rubella- given to females greater than 13 years who do not have documented immunity
Children need 2 doses at 12-15 months and 4-6 years
Varicella *
Live
Localized pain, erythema; some may develop rash
Rotavirus *
Live
History of intussusception or SCID is contraindicated
Small pox *
Live
Given only for risk of outbreak
Yellow fever vaccine *
Given for travel to countries when it is endemic or pandemic
Passive immunity *
Derived from sera of pooled human IG, illness borne IG, antibodies from animal or monoclonal antibodies
For those with immunodeficiency or have issues making antibodies
For non immunized or under immunized patients exposed to certain infectious diseases
CMV immune globulin
Hep B immune globulin
Immune globulin intravenous
Rabies immune globulin
Respiratory syncytial virus
Tetanus immune globulin
Varicella zoster immune globulin
RSV prophylaxis *
Palivizumab for infants at risk for adverse outcomes of RSV
Infants born before 29 weeks during RSV season until they are 12 months
Children born less than 32 weeks who are less than 2 years and who have chronic lung disease
Infant up to 12 mths old with hemodynamically significant cyanotic or complicated continental heart disease
Infants up to 12 months old with neuromuscular disorder or congenital anomalies compromising respiratory secretion
Herpes zoster *
Shingles, shingrix
Indicates for shingles and post therapeutic neuralgia
Immunocompotent age 50
2 doses 2-6 months apart
Covid 19 *
Convalescent plasma
Vaccine-pzier and Moderna, J&J
Immunosuppressants *
Reduce the activity efficiency of the immune system to treat auto immune diseases or to lower the bodies ability to reject organ transplant
Regiments typically consist of 2 to 4 agents with different mechanisms of action that disrupt the various levels of T cell activation
Three parts of immune activation
-Part one-T cells trigger at the CD3 receptor complex spine antigen on the surface of an antigen presenting cell
-part two-costimulation- where is CD 80 and CD 86 on the surface of the APC engage Cd 28 on T cells this activates many pathways, including calcium calcneurin pathway, this activation triggers of production of IL2 that binds to IL2 receptors on the surface of T cells
-part 3- activation of the cell cycle via the mammalian target of rapamycin and leading to T cell proliferation
More potent actors- monoclonal antibodies
Maintenance-less potent but long term protection
Antithymocyte globulins *
Class- polyclonal antibodies
MOA- cause complete depletion of T cell circulating and apoptosis of activated T cells
Uses- prevention of rejection of allograft transplant in use with other immunosuppressants, severe rejection episodes, corticosteroid resistant acute rejection
Premedication with steroids, APAP, antihistamines
ADE- prolong use can result in profound immunosuppression, increased risk of infection, post transplant lymphoproliferative disease
Basiliximab (simulect) *
Class- chimeric murine/human monoclonal antibody
MOA- binds to alpha chain on IL 2 receptor on activated T cells, interferes with proliferative cells
Uses- acute rejection in renal transplant in combo with cyclosporine, and corticosteroids, for reduce graft function, decreased risk of calcineurin inhibitor renal toxicity, and rejection prophylaxis
ADE- well tolerated, HTN, GI distress, increased risk for OI, lymphoproliferative disease